Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. - Wikidata - wikimedia - TriplyDB

Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

http://www.wikidata.org/entity/Q34770459

about

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study.Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.Tocilizumab for treating juvenile idiopathic arthritis.Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system.Prodromal signs and symptoms of serious infections with tocilizumab treatment for rheumatoid arthritis: Text mining of the Japanese postmarketing adverse event-reporting database.Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Resu ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.Tocilizumab: A Review in Rheumatoid Arthritis.Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.Weekly subcutaneous injection of tocilizumab in patients with rheumatoid arthritis.A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.

P2860

Q24185797-0B75C995-A75A-4554-8FC3-65A74A45680F Q28080677-D3E6B118-B5C9-4D7C-85DA-F6CDACECD0B1 Q30234528-1D7702C4-7C4A-4219-B51C-763E95A40307 Q30235341-265A0C66-5598-4318-ACAF-46C9EA522CF9 Q31137082-71F0B253-842A-47C2-BE64-B5761843232C Q31151183-E806D314-2E1D-4874-86C2-E4B3B0575655 Q33725505-17D3EDBB-D879-4780-91FC-7176D570FA7A Q33809045-67DE5077-8AD6-48D2-A8B2-19ED9538BDF8 Q36195284-00B79D9D-A520-4745-B66B-5A696B483589 Q36249305-2366632F-00B4-467A-B720-6DD33401C048 Q37320282-75B70CFA-194C-44B2-B4BF-D965D43C4463 Q37453033-72F9AB8C-13BA-475F-B905-47ACEEE762B8 Q38305522-FE8CB9C0-3C68-4995-BAE1-DE378A6B64C6 Q38371450-671F3A96-A2A4-468A-96F5-FC1FA7BA0D2D Q38411334-C147D2D3-CCE7-4B51-B9D1-197C725DC351 Q38617817-B6878FA1-F871-431D-91C6-3D16A6FA27A1 Q38723988-F8E40C61-474E-429D-B7C7-E1B526E5E523 Q38828876-453C44F8-5FF8-4F0A-A96C-0BA06965F28B Q39066090-27A38B8E-E0AC-460F-85F9-B43C6D4492BD Q40062836-985DDFBF-397C-4433-BB49-6B0DE11085DC Q40167433-4795AC35-65C8-4925-B8C5-BE056FE43A42 Q40169728-54F8061B-9D2E-4E3A-8CB5-9E61BF500161 Q40377000-143098B1-DB15-42D9-8BBD-1E50B52EDDCD Q42090806-DC83809F-7EF8-467A-80CC-F0E6EE4E9B95 Q42146734-9FAE460D-BFFF-4359-A88F-8011A13F2E52 Q43280791-038EC832-3180-445D-A4F0-F5DB1FA2E2C1 Q47292924-1517327C-E144-4C4F-908F-618BAA560C38 Q49518769-2168A6B0-9DCF-4003-A46D-A1D17AA74485 Q49824861-DF6A9F07-571B-468B-AB6D-1AF5BBD80636 Q50086845-C8F46AB9-5AD5-4794-AB76-9736AE5B59FD Q52675492-9343548E-7ECE-4533-A235-CFE2B079C10F Q55396986-086FF36A-9928-410C-9803-C5E236655CBC

P2860

Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

http://www.wikidata.org/entity/Q34770459

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.

@ast

Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.

@en

Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.

@nl

type

label

Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.

@ast

Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.

@en

Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.

@nl

prefLabel

Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.

@ast

Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.

@en

Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.

@nl

P1433

Q34770459-FD1D28CB-497E-447E-BF4C-35457B85C7F7

P1476

Q34770459-63DA5872-E0DD-4550-8E13-ADD31D508236

P2093

Q34770459-44E2343A-1920-4C51-B9F8-9C7EF5549E04

Q34770459-5AA13CB4-95E0-463A-94DE-FCBBA9728647

Q34770459-6C1D5BA8-67C1-4876-A87C-8110D2FF88A8

Q34770459-6F426170-AA9F-4114-B3AE-6DA7FFF74530

Q34770459-759397F0-5671-4898-823A-5523A7D92187

Q34770459-7E162B99-F3A1-40B0-B058-2B48A1EA6098

Q34770459-A04D4C86-3985-4EFC-9801-F2C088D23613

Q34770459-C4882AA4-A3E0-428F-82C9-A5A8219CB6D8

Q34770459-C8D239F2-CDC8-4531-8CC9-BDEE510E7D66

Q34770459-DC849F04-36DB-41A6-8D2A-581885460161

P2860

Q34770459-0481408A-521C-47CD-B5AB-2427CA3CA3DD

Q34770459-08BE5AD3-820D-40F4-BBD0-E6AF09ED2832

Q34770459-13C0EEB5-2A27-46E4-8051-C580615BD1C4

Q34770459-2B422DEF-1A78-4E00-BA17-4CA7023CC358

Q34770459-3F91849C-02F5-4787-8AD8-BB2B6278AF41

Q34770459-470E21A2-D2AB-4168-A4DC-D8AA7F12D0E7

Q34770459-47234FE0-C4F8-490E-B249-E926C9E1D0C1

Q34770459-684690C5-AD14-4F09-8546-535D5B3EA9B4

Q34770459-81AC777D-143E-40ED-8DC4-5A13E61C1261

Q34770459-B7F2F75D-E31D-400B-9811-B00F9096FFF7

P304

Q34770459-938E2E64-02A3-4D39-BA93-15E67B34AA8E

P31

Q34770459-FDA5A675-2E19-43CE-BA78-55F4120CE995

P356

Q34770459-BA249A1F-6FF0-4CBE-ABE8-35C2A8CAB883

P433

Q34770459-DE77660E-3318-4710-8315-0F3565FB85B4

P478

Q34770459-D8A504C8-42B7-472A-A7E4-7C6CC64FF9D0

P50

Q34770459-B7E2F84B-73E1-402A-94BA-274780B23BC7

P577

Q34770459-D38DF044-6BAA-4070-8A55-19D4ACB670F8

P5875

Q34770459-75D07567-FBFA-44A8-B1DB-4FECE3F10F5E

P698

Q34770459-C9D68D73-AEAC-40E0-BE85-8AC273B9BB89

P921

Q34770459-432D6C05-1CB2-4D83-9DCA-8BBAE60911AA

P932

Q34770459-DA6FE9ED-48C5-48E2-BBC7-E9A621214F6A

P356

P1433

Arthritis Care and Research

P1476

Subcutaneous tocilizumab versu ...... nts with rheumatoid arthritis.

@en

P2093

Alan Kivitz

http://www.w3.org/2001/XMLSchema#string

Beatriz M Zazueta

http://www.w3.org/2001/XMLSchema#string

Clare Nasmyth-Miller

http://www.w3.org/2001/XMLSchema#string

Ewa Olech

http://www.w3.org/2001/XMLSchema#string

Federico Navarro-Sarabia

http://www.w3.org/2001/XMLSchema#string

Joan T Merrill

http://www.w3.org/2001/XMLSchema#string

Lucy Rowell

http://www.w3.org/2001/XMLSchema#string

Michael Borofsky

http://www.w3.org/2001/XMLSchema#string

Min Bao

http://www.w3.org/2001/XMLSchema#string

Sebastião C Radominski

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

P304

1653-1661

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACR.22384

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263321837

http://www.w3.org/2001/XMLSchema#string

P698

24942540

http://www.w3.org/2001/XMLSchema#string

P921

P932

4276289

http://www.w3.org/2001/XMLSchema#string